Jivanu Therapeutics

Jivanu Therapeutics is a pre-clinical stage biotechnology company pioneering the development of engineered microbial therapies for the treatment of solid tumors. The company's platform utilizes synthetic biology to program probiotic bacteria to selectively colonize the tumor microenvironment and deliver potent therapeutic payloads locally. This approach aims to overcome the limitations of systemic drug delivery by providing high local concentrations of medicine while minimizing off-target toxicities. Jivanu is currently advancing a pipeline of live biotherapeutic products designed to activate the immune system and enhance the efficacy of existing cancer treatments. By leveraging the natural affinity of certain bacteria for the hypoxic regions of tumors, the company seeks to create a new pillar of precision oncology.